Back to top
more

Generation Bio (GBIO)

(Real Time Quote from BATS)

$4.37 USD

4.37
5,782

-0.19 (-4.17%)

Updated Aug 6, 2025 10:50 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Generation Bio Co. (GBIO) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Generation Bio (GBIO) delivered earnings and revenue surprises of 12% and 464.23%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Generation Bio Co. (GBIO) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Generation Bio (GBIO) delivered earnings and revenue surprises of -14.29% and 6.95%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Gossamer Bio (GOSS) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Gossamer Bio (GOSS) delivered earnings and revenue surprises of 11.76% and 19.63%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Generation Bio Co. (GBIO) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Generation Bio (GBIO) delivered earnings and revenue surprises of 17.86% and 249.24%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Vertex Pharmaceuticals (VRTX) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Vertex (VRTX) delivered earnings and revenue surprises of 6.05% and 3.62%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Generation Bio Co. (GBIO) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Generation Bio (GBIO) delivered earnings and revenue surprises of -14.81% and 26.85%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Protagonist Therapeutics (PTGX) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 0% and 89.58%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Generation Bio Co. (GBIO) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Generation Bio (GBIO) delivered earnings and revenue surprises of -211.11% and 34.63%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Generation Bio Co. (GBIO) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Generation Bio Co. (GBIO) delivered earnings and revenue surprises of -29.27% and 5.64%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Generation Bio Co. (GBIO) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Generation Bio Co. (GBIO) delivered earnings and revenue surprises of 4.08% and 88.27%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Generation Bio Co. (GBIO) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Generation Bio Co. (GBIO) delivered earnings and revenue surprises of -35.90% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Moderna (MRNA) Inks Genetic Medicines Deal With Generation Bio

by Zacks Equity Research

Moderna (MRNA) collaborates with Generation Bio to develop non-viral genetic medicines. For this, it leverages the latter's closed-end DNA (ceDNA) and cell-targeted LNPs (ctLNP) technologies.

Zacks Equity Research

Can Generation Bio Co. (GBIO) Climb 184% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 183.8% in Generation Bio Co. (GBIO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Wall Street Analysts Think Generation Bio Co. (GBIO) Could Surge 176%: Read This Before Placing a Bet

by Zacks Equity Research

The consensus price target hints at a 176% upside potential for Generation Bio Co. (GBIO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

Generation Bio Co. (GBIO) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Generation Bio Co. (GBIO) delivered earnings and revenue surprises of -4.76% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Wall Street Analysts See a 174% Upside in Generation Bio Co. (GBIO): Can the Stock Really Move This High?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 173.7% in Generation Bio Co. (GBIO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Generation Bio Co. (GBIO) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Generation Bio Co. (GBIO) delivered earnings and revenue surprises of -17.31% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Generation Bio Co. (GBIO) Upgraded to Buy: Here's Why

by Zacks Equity Research

Generation Bio Co. (GBIO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

How Much Upside is Left in Generation Bio Co. (GBIO)? Wall Street Analysts Think 505%

by Zacks Equity Research

The consensus price target hints at a 504.9% upside potential for Generation Bio Co. (GBIO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

Why Earnings Season Could Be Great for Generation Bio (GBIO)

by Zacks Equity Research

Generation Bio (GBIO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

Generation Bio (GBIO) Catches Eye: Stock Jumps 6.1%

by Zacks Equity Research

Generation Bio (GBIO) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.